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Abstract
Background: Integrin-extracellular matrix interactions activate signaling cascades such as mitogen
activated protein kinases (MAPK). Integrin binding to extracellular matrix increases tyrosine
phosphorylation of focal adhesion kinase (FAK). Inhibition of FAK activity by expression of its
carboxyl terminus decreases cell motility, and cells from FAK deficient mice also show reduced
migration. Paxillin is a focal adhesion protein which is also phosphorylated on tyrosine. FAK
recruitment of paxillin to the cell membrane correlates with Shc phosphorylation and activation of
MAPK. Decreased FAK expression inhibits papilloma formation in a mouse skin carcinogenesis
model. We previously demonstrated that MAPK activation was required for growth factor induced
in vitro migration and invasion by human squamous cell carcinoma (SCC) lines.
Methods:  Adapter protein recruitment to integrin subunits was examined by co-
immunoprecipitation in SCC cells attached to type IV collagen or plastic. Stable clones
overexpressing FAK or paxillin were created using the lipofection technique. Modified Boyden
chambers were used for invasion assays.
Results: In the present study, we showed that FAK and paxillin but not Shc are recruited to the
β1 integrin cytoplasmic domain following attachment of SCC cells to type IV collagen.
Overexpression of either FAK or paxillin stimulated cancer cell migration on type IV collagen and
invasion through reconstituted basement membrane which was dependent on MAPK activity.
Conclusions: We concluded that recruitment of focal adhesion kinase and paxillin to β1 integrin
promoted cancer cell migration via the mitogen activated protein kinase pathway.
Background
Integrin extracellular domains bind extracellular matrix
molecules such as type IV collagen and laminin while the
cytoplasmic domains bind specific components of the
actin cytoskeleton [1]. Integrin-extracellular matrix inter-
actions also activate signaling cascades such as mitogen
activated protein kinases [2]. Integrin binding to extracel-
lular matrix or integrin crosslinking increases tyrosine
phosphorylation of focal adhesion kinase (FAK) [3]. FAK
consists of a central catalytic domain and amino and car-
boxyl terminal non- catalytic domains. A focal adhesion
targeting sequence within the carboxyl terminus is
required for localization to focal adhesions [4]. FAK
undergoes autophosphorylation on a single tyrosine
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residue which creates a binding site for SH2 containing
proteins. Inhibition of FAK activity by expression of its
carboxyl terminus decreases cell motility, and cells from
FAK deficient mice also show reduced migration [5,6].
Paxillin is a focal adhesion protein which is also phospho-
rylated by a number of stimuli on tyrosine [2]. Paxillin
interacts with FAK at two sites in the amino and carboxyl
termini which are not required for targeting paxillin to
focal adhesions [7]. A mutant paxillin protein lacking
both FAK binding sites exhibits reduced tyrosine phos-
phorylation [8]. FAK recruitment of paxillin to the cell
membrane correlates with Shc phosphorylation and acti-
vation of the MAPKs ERK and JNK [9]. However JNK
phosphorylation is not dependent on FAK nor on phos-
phatidylinositol 3-kinase (PI3K) activity.
Transformation of FAK deficient fibroblasts with the v-Src
oncogene promotes cellular motility equal to that of FAK
re-expression [10]. However, these cells are not invasive
and required intact FAK expression to produce this pheno-
type. Decreased FAK expression inhibits papilloma forma-
tion in a mouse skin carcinogenesis model [11]. These
studies indicate that FAK has a key role in tumorigenesis
and invasion. We previously demonstrated that PI3K,
ERK, and JNK activation were required for growth factor
induced in vitro migration and invasion by human squa-
mous cell carcinoma (SCC) lines [12,13]. These studies
led us to hypothesize that FAK and paxillin may mediate
signals from the substratum via ERK in order to regulate
cell migration. In the present study, we show that FAK and
paxillin but not Shc are recruited to the β1 integrin cyto-
plasmic domain following attachment of SCC cells to type
IV collagen. This recruitment correlated with increased
cellular migration on this substratum. Overexpression of
either FAK or paxillin stimulated cancer cell migration on
type IV collagen and migration through reconstituted
basement membrane which was dependent on ERK activ-
ity. We concluded that recruitment of focal adhesion
kinase and paxillin to β1 integrin promoted cancer cell
migration and invasion via the mitogen activated protein
kinase pathway.
Methods
Cell culture and stable transfection
SCC4 and SCC25 cells were cultured in Dulbecco's modi-
fied Eagle medium (DMEM), 10% fetal bovine serum, 40
µg/ml gentamicin at 37°C in a humidified atmosphere of
5% CO2. Cells were plated on tissue culture plastic dishes
or commercially available plates coated with type IV col-
lagen (Becton Dickinson). Some cells were pretreated
with blocking antibodies to β1 or β4 integrins (Invitro-
gen) for 1 hour prior to plating [14,15]. Other cultures
were deprived of attachment by plating on uncoated petri
dishes in media containing 1.6% methylcellulose. Cells
were transfected with 5 µg expression vector for FAK or
paxillin (kindly provided by Dr. Thomas Parsons) or neo-
mycin resistance plasmid alone using Lipofectamine rea-
gent according to manufacturer's recommendations
(Invitrogen). Cells were selected in 400 µg/ml G418 for
14 days. Resistant clones were picked for expansion and
characterization. FAK and paxillin expression was deter-
mined by western blot.
Immunoprecipitation
Cultures were lysed in 50 mM HEPES (pH 7.5), 150 mM
NaCl, 1 mM EDTA, 2.5 mM EGTA, 1 mM DTT, 1% Noni-
det P-40, 10% glycerol, 1 mM NaF, 0.1 mM sodium
orthovanadate, and protease inhibitors for 30 minutes at
4°C. Lysates were centrifuged at 10,000 × g for 10 minutes
and anti-β1 integrin antibody (Invitrogen) was incubated
with the supernatants for 1 hour at 4°C. Antigen-antibody
complexes were precipitated with protein A/G agarose
beads for 1 hour at 4°C. Samples were boiled in Laemmli
buffer for 3 minutes, separated by SDS-PAGE, and blotted
to polyvinylidene difluoride membranes. Blots were incu-
bated with anti-FAK, paxillin (Transduction Laborato-
ries), Shc, and Grb2 (Santa Cruz Biotechnology)
antibodies to determine relative association with β1
integrin. Blots were then incubated with anti-β1 integrin
antibody to ensure equal amounts of immunoprecipi-
tated protein in each lane. Bands were analyzed by laser
densitometry and the numerical data subjected to t test.
Western blot
75 µg total cellular protein was separated by SDS-PAGE
on 10% resolving gels under denaturing and reducing
conditions. Separated proteins were electroblotted to
PVDF membranes according to manufacturer's recom-
mendations (Roche Molecular Biochemicals). Blots were
incubated with antibodies to human FAK, paxillin, ERK1,
activated ERK1 (Transduction Laboratories), or β1
integrin (Invitrogen) for 16 hours at 4°C. After washing in
Tris buffered saline containing 0.1% Tween 20 (TBST, pH
7.4), blots were incubated for 30 minutes at room temper-
ature with anti-IgG secondary antibody conjugated to
horseradish peroxidase. Following extensive washing in
TBST, bands were visualized by the enhanced chemilumi-
nescence method (Roche Molecular Biochemicals). Bands
were analyzed by laser densitometry and the numerical
data subjected to t test.
Migration and invasion assays
Cells were plated at confluence on plastic in the presence
or absence of type IV collagen for 24–48 hours. Some cells
were pretreated with blocking antibodies to β1 or β4
integrins for 1 hour prior to plating. Other cultures were
treated with 50 µM PD98059, a selective inhibitor of ERK
activation. The dishes were scored with a pipet tip across
the center of the plate. The number of cells whichBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/18
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migrated into the blank area of the dish during the speci-
fied time period was determined by counting of 10 ran-
dom fields using phase contrast microscopy. For invasion
assays, 2 × 105 cells were plated in triplicate into commer-
cially available Matrigel invasion chambers (Becton Dick-
inson). Cells which migrated through the reconstituted
basement membrane after 24 hours were fixed in metha-
nol, stained with hematoxylin, and counted.
Results
Integrin binding to extracellular matrix increases associa-
tion of the intracellular domain with FAK and paxillin
[3,7]. To determine if FAK and paxillin could interact with
the β1 integrin subunit in human SCC lines, we immuno-
precipitated this receptor from SCC4 and SCC25 cells cul-
tured in suspension, plated on tissue culture plastic, or
attached to type IV collagen. As shown in Fig. 1A and 1B,
4 fold more FAK protein associated with β1 integrin sub-
unit when cells were plated on both plastic and type IV
collagen compared to anchorage deprived cells (p <
0.00001). Preincubation with a blocking antibody to β1
integrin but not β4 integrin inhibited the association of
FAK with β1 integrin when cells were plated on type IV
collagen. Paxillin was also recruited to the β1 integrin
complex when cells were plated on plastic (2 fold, p <
0.03) or type IV collagen (5 fold, p < 0.00001) but not
when the cells were anchorage deprived. Incubation with
blocking antibody to β1 integrin also inhibited the associ-
ation of paxillin with the integrin subunit in cells plated
on type IV collagen (5 fold, p < 0.03). Blocking antibodies
failed to inhibit FAK or paxillin recruitment when cells
were plated on plastic, indicating that the antibody effec-
tively blocked attachment to type IV collagen. However
the blocking antibodies did not inhibit cell attachment
since the cells could also adhere to the tissue culture plas-
tic dishes via charge interactions. In contrast, the 52 kd
Shc isoform was detected in the β1 integrin complex only
when cells were anchorage deprived. Shc association was
not detected in plated cells regardless of substratum or
antibody preincubation (p < 0.05). Grb2 associated with
β1 integrin under all conditions, indicating that the
observed changes in FAK, paxillin, and Shc binding were
specific. Similar results were obtained using the SCC4 cell
line. These results indicated that FAK and paxillin were
recruited to β1 integrin when cells were attached to sub-
stratum while Shc was associated with the receptor in
anchorage deprived cells.
FAK deficient cells are less migratory than their normal
counterparts [6], and our data indicated that attachment
to type IV collagen increased paxillin association with β1
integrin when compared to plastic. To determine if FAK
and paxillin association with β1 integrin correlated with
increased migration, we plated SCC4 and SCC25 cells on
plastic or type IV collagen with or without preincubation
with integrin blocking antibodies. As shown in Fig. 2,
attachment to type IV collagen produced a greater than 2
fold increase in the number of cells which migrated into a
blank area of the culture dish. This migration was mark-
edly inhibited by preincubation with blocking antibody
to β1 integrin but not to β4 integrin. Integrin blocking
antibodies had no effect on cellular migration on plastic,
indicating that the antibodies effectively blocked attach-
ment to extracellular matrix. Similar results were obtained
FAK and paxillin immunoprecipitate with β1 integrin follow- ing cell attachment to type IV collagen Figure 1
FAK and paxillin immunoprecipitate with β1 integrin follow-
ing cell attachment to type IV collagen. SCC25 cells were 
plated in semisolid media (susp), on tissue culture plastic (pl), 
or on type IV collagen (col) for 2 hours. Some cultures were 
preincubated with antibodies which block attachment by β1 
or β4 integrin subunits. β1 integrin was immunoprecipitated 
(IP β1) from cell lysates and western blotted using the anti-
bodies indicated at left. These experiments were performed 
three times with similar results. Representative blots are 
shown. (B) Densitometric quantitation of blots in Fig. 1A.BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/18
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with SCC4 cells. These results indicated that FAK and pax-
illin recruitment to β1 integrin correlated with increased
migration on type IV collagen.
FAK overexpression has been associated with increased
tumor invasion and lymph node metastasis in clinical
cases of human cancer [16]. To determine if FAK and pax-
illin overexpression produced increased in vitro migration
of cancer cell lines, we stably transfected each expression
vector into SCC4 and SCC25 cells. FAK and paxillin pro-
teins were up to 20 fold overexpressed in these stable
clones (Fig. 3A,3B; p < 0.05). Both FAK and paxillin over-
expression effectively induced migration in SCC25 cells
(Fig. 3C). FAK overexpression induced migration by 6 fold
while paxillin overexpression increased motility by 3 fold
when cells were plated on plastic dishes. Migration was
further enhanced when cells were plated on type IV colla-
gen. Migration was induced 7 fold when FAK overexpress-
ing cells were plated on type IV collagen compared to
controls. Paxillin overexpressing cells were also more
migratory on type IV collagen than on plastic; however
there was no additive effect of type IV collagen attachment
in these clones. Blocking antibody to β1 integrin inhibited
migration of FAK and paxillin overexpressing clones on
type IV collagen but not on plastic. Blocking antibody to
β4 integrin had no effect on cell migration on either sub-
stratum. We were unable to obtain stable clones express-
ing the 52 kD Shc isoform due to terminal differentiation
of these clones (see Discussion). Similar results were
obtained with SCC4 cells. These results indicate that FAK
and paxillin overexpression promote migration of human
SCC lines which is enhanced by β1 integrin attachment to
a relevant substratum.
FAK recruitment of paxillin to the cell membrane results
in activation of the MAPK pathway [9]. To determine if
the MAPK pathway contributed to FAK and paxillin
induced migration, we plated these clones on type IV col-
lagen coated dishes and treated the cells with PD98059, a
selective upstream inhibitor of ERK1 activation. PD98059
treatment reduced ERK1 activation by up to 3 fold as
determined by western blot using an anti-phosphoERK1
antibody (Fig. 4A,4B; p < 0.003). Treatment of FAK and
paxillin overexpressing clones with PD98059 inhibited
migration on type IV collagen by 75% (Fig. 4C). However
treatment with this inhibitor had little effect on basal
migration of control clones, which correlated with our
published work [13]. Four to six fold more FAK and pax-
illin overexpressing cells were able to invade through
reconstituted basement membrane in the Matrigel inva-
sion assays (Fig. 4D) which correlated with the migration
experiments. MEK inhibition with PD98059 also inhib-
ited invasion by FAK and paxillin overexpressing clones.
These results indicated that MAPK inhibition could
decrease FAK and paxillin induced migration and inva-
sion by human SCC cells.
Discussion
The results of this study demonstrated that FAK and paxil-
lin were recruited to the β1 integrin subunit when cells
were plated on plastic or type IV collagen. However, the
52 kD isoform of the Shc adaptor protein was present in
the complex only when cells were maintained under
anchorage deprived conditions. Stratified squamous epi-
thelial cells ultimately undergo terminal differentiation
when deprived of attachment [17], and 52 kD Shc overex-
pression was sufficient in our study to produce terminal
differentiation of cells plated on plastic tissue culture
dishes. These results suggest that localization of 52 kD Shc
to integrin signaling complexes may regulate terminal dif-
ferentiation of stratified squamous epithelial cells follow-
ing loss of basement membrane attachment. Shc is known
to regulate growth factor receptor induction of the MAPK
pathway [18]; it will be interesting to determine if MAPK
inhibition prevents anchorage deprived terminal differen-
tiation of stratified squamous epithelial cells.
In this context, FAK has been shown to suppress anchor-
age deprived cell death in MDCK cells [19]. The kinase
activity and autophosphorylation site of the protein is
required for this effect. FAK inhibition by overexpression
of the carboxyl terminal domain causes loss of adhesion
and cell death in human breast cancer lines [20]. Simi-
larly, anchorage independent breast cancer cells undergo
apoptosis when FAK function is disrupted. Interestingly,
the FAK carboxyl terminus has no effect on adhesion or
Type IV collagen stimulates β1 integrin dependent migration  of SCC25 cells Figure 2
Type IV collagen stimulates β1 integrin dependent migration 
of SCC25 cells. SCC25 cells were plated on plastic (pl) tissue 
culture dishes or type IV collagen (col) coated plates. Some 
cultures were preincubated with antibodies which block 
attachment by β1 or β4 integrin subunits. The number of 
cells which migrated into the blank area of the plate within 
24 hours was counted. These experiments were performed 
three times with similar results. Error bars indicate SEM.BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/18
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FAK and paxillin promote SCC migration on type IV collagen in a β1 integrin dependent manner Figure 3
FAK and paxillin promote SCC migration on type IV collagen in a β1 integrin dependent manner. (A) Overexpression of FAK 
and paxillin in SCC25 cells. FAK and paxillin expression vectors were stably transfected into SCC25 cells as described in Mate-
rials and Methods. FAK and paxillin expression was determined in neomycin resistant control (neo), FAK overexpressing 
(FAK-1, -2), and paxillin overexpressing (pax-1, -2) clones by western blot using anti-FAK and anti-paxillin (anti-pax) antibodies. 
This experiment was repeated with additional independently isolated clones with similar results. Representative blots are 
shown. (B) Densitometric quantitation of blots in Fig. 3A. (C) FAK or paxillin (pax) overexpressing clones or neomycin resist-
ant control cells (neo) were plated on plastic (pl) tissue culture dishes or type IV collagen (col) coated plates. Some cultures 
were preincubated with antibodies which block attachment by β1 or β4 integrin subunits. The number of cells which migrated 
into the blank area of the plate within 24 hours was counted. These experiments were performed three times with similar 
results. Error bars indicate SEM.BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/18
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FAK and paxillin induce SCC migration via activation of the mitogen activated protein kinase ERK1 Figure 4
FAK and paxillin induce SCC migration via activation of the mitogen activated protein kinase ERK1. (A) Neomycin resistant 
control (neo), FAK overexpressing, and paxillin overexpressing (pax) clones were treated with the MEK inhibitor PD98059 
(PD) or vehicle as described in Materials and Methods. Relative phosphorylated ERK1 and total ERK1 expression was deter-
mined by western blot using anti-phosphoERK1 (anti-pERK1) and anti-ERK1 antibodies. This experiment was repeated with 
additional independently isolated clones with similar results. Representative blots are shown. (B) Densitometric quantitation of 
blots in Fig. 4A. (C) FAK or paxillin (pax) overexpressing clones or neomycin resistant control cells (neo) were plated on plas-
tic tissue culture dishes and treated with the MEK inhibitor PD98059 (PD) or vehicle as described in Materials and Methods. 
The number of cells which migrated into the blank area of the plate within 24 hours was counted. (D) FAK or paxillin (pax) 
overexpressing clones or neomycin resistant control cells (neo) were plated into Matrigel invasion chambers and treated with 
the MEK inhibitor PD98059 (PD) or vehicle. The number of cells which migrated through the reconstituted basement mem-
brane were fixed, stained, and counted. These experiments were performed three times with similar results. Error bars indi-
cate SEM.BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/18
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viability of normal mammary epithelial cells. FAK has
been shown to activate JNK which then colocalizes at
focal adhesions in primary fibroblasts [21]. This activa-
tion occurs via a Ras/Rac1/Pak1/MKK4 pathway. In the
presence of serum, survival signals are also transduced by
PI3K and Akt. These studies suggest that FAK is also
required for survival signaling from the extracellular
matrix. Our future studies will examine this property of
FAK in human SCC lines.
Our results demonstrated that FAK and paxillin induced
migration and invasion of SCC lines was dependent on
ERK activity. In colon cancer cell lines, cell attachment to
collagen or laminin stimulates phosphorylation of FAK
and paxillin and activates ERK1 [22]. FAK inhibition
reduces attachment dependent ERK1 activation. ERK1
inhibition reduced migration of colon cancer cells [23],
and inhibited growth factor induced migration in SCC
lines used in the present study. FAK inhibition also dis-
rupted growth factor stimulated migration of human lung
cancer cells [24]. These studies highlight an important
role for ERK signaling in mediating collagen induced
migration and invasion of human cancer cell lines. FAK
expression has been correlated with tumor invasion and
lymph node metastasis of cancer cells [16]. In this study,
FAK overexpression was detected in 59% of esophageal
cancer pathology specimens. This overexpression was
associated with decreased cellular differentiation, late
clinical stage, increased depth of invasion, poor survival
rate, and lymph node metastasis. Future clinical studies
may examine FAK inhibition as potential antitumor
therapy.
Conclusions
FAK and paxillin were recruited to β1 integrin when cells
were attached to substratum while Shc was associated
with the receptor in anchorage deprived cells. FAK and
paxillin recruitment to β1 integrin correlated with
increased migration on type IV collagen. FAK and paxillin
overexpression promote migration of human SCC lines
which is dependent on β1 integrin attachment to its phys-
iologic substratum. MAPK inhibition could decrease FAK
and paxillin induced migration and invasion of human
SCC cells.
List of abbreviations
ERK extracellular signal regulated kinase
FAK focal adhesion kinase
Grb2 growth factor receptor bound protein 2
JNK jun N-terminal kinase
PI3K phosphatidylinositol 3-kinase
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